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Abstract 
 Harm reduction in cardiovascular disease is a significant problem worldwide. Providers, 
families, and healthcare agencies are feeling the burdens imparted by these diseases. Not to 
mention missed days of work and caregiver strain, the losses are insurmountable. Motivational 
interviewing (MI) is gaining momentum as a method of stimulating change through intrinsic 
motivation by resolving ambivalence toward change (Ma, Zhou, Zhou, & Huang, 2014). If 
practitioners can find methods of educating the public in a culturally-appropriate and sensitive 
manner, and if they can work with community stakeholders to organize our resources to make 
them more accessible to the people, we may find that simple lifestyle changes can lead to risk 
reduction of cardiovascular diseases. By working with our community leaders and identifying 
barriers unique to each population, we can make positive impacts on a wide range of issues 
that markedly impact our healthcare systems.  
 
Keywords: Motivational interviewing, hypertension, risk reduction, harm reduction, 
cardiovascular events, community, population, self-management, self-efficacy, behavior 
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Motivational Interviewing Impact on Cardiovascular Disease 
 Hypertension occurs in 1 in 3 Americans, making this the most common condition 
treated in primary care (Kravetz & Walsh, 2016; Office of Disease Prevention and Health 
Promotion, 2019). Providers are struggling with reducing cardiovascular risk factors, and they 
cannot understand why. Matters are further complicated when patients have poor medication 
adherence, low socioeconomic status, cultural or language barriers, and lack of exercise and 
healthy eating habits. Patients may struggle with the ability to afford their medications, 
sometimes choosing to cut their pills in half or not refill their prescriptions so that they can put 
food on the table. Others may have difficulty reaching a pharmacy or grocery store. 
Background and Significance 
Incidence and Prevalence 
 With a recent change in the national guidelines to now consider hypertension 130/80 or 
above, an already flooded healthcare system will now be inundated with new hypertensive 
patients, and those already on medication will need tighter control (Ioannidis, 2018). According 
to the World Health Organization (2019), the global prevalence of hypertension in adults aged 
25 and over was around 40% in 2008; nearly one billion. The Centers for Disease Control and 
Prevention (2017) estimates that 33.2% of adults aged 20 and over have hypertension. During 
2015–2016, the prevalence of hypertension in the United States was 29.0% and increased with 
age (Centers for Disease Control and Prevention, 2017). In Arizona, 22.3 percent of the adult 
population reported they had high blood pressure in 2005 (Arizona Department of Health 
Services, n.d.). 
Compliance 
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 Up to 54% of patients do not take their medications as prescribed (Centers for Disease 
Control and Prevention, 2017; Kravetz & Walsh, 2016; Office of Disease Prevention and 
Health Promotion, 2019). It is in the interest of patients, insurance agencies, federal 
organizations, and communities to prevent complications of hypertension. Such complications 
include heart attack, stroke, cardiovascular disease, sick days and caregiver strain. Efforts are 
directed at increasing compliance with medication adherence and lifestyle modifications, such as 
diet and exercise (Ma, Zhou, Zhou, & Huang, 2014). It is the responsibility of healthcare 
providers to determine what kinds of barriers are preventing patients from seeking or maintaining 
their health and wellness. It is also the duty of each member of the healthcare team to work with 
the patient and their support system to implement a plan of care that is achievable and culturally 
competent (Zaccagnini & White, 2017). Hypertension is also known as the silent killer, which 
makes this a larger threat to the nation, as many are unaware that they are suffering from this 
disease. It is important that methods of addressing this healthcare crisis be further evaluated.  
Purpose and Rationale 
 Half of all Americans suffer from some form of cardiovascular disease (American 
Heart Association, 2019). In 2016, heart disease was the number one cause of death in the 
United States (American Heart Association, 2019; Office of Disease Prevention and Health 
Promotion, 2019). Hypertension can lead to heart disease and stroke, which is why it must be 
addressed (American Heart Association, 2019). A primary school district in Arizona has 
identified risk reduction of cardiovascular events as a problem. This school is interested in 
harm reduction interventions. Lack of education, patient compliance, and scarcity of resources 
have led to poor outcomes regarding heart disease in this population. Simple interventions, 
such as limiting sodium intake, can significantly improve cardiovascular measures, but have 
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failed to do so (Office of Disease Prevention and Health Promotion, 2019). Key stakeholders 
are receptive to trialing any means necessary to improve cardiovascular disease. Much research 
has already been done on hypertension management and yet implementation has failed to make 
significant improvements nationally. Treating each community with a unique and tailored 
approach to risk reduction may yield greater impacts in the field of chronic disease 
management.  
 Studies suggest that if blood pressure is kept below 130/80, patients will have better 
outcomes (Ghazi & Oparil, 2018; Kirk, Allsbrook, Hansell, & Mann, 2017). Depending on age 
and other factors, such as cardiovascular comorbidities, goals for hypertension management 
were variable until the recent guideline recommendations changed (American Heart 
Association, 2019; Kirk et al., 2017). The American Heart Association, along with the 
American College of Cardiology (2017) now recommend a blood pressure goal of 130/80, 
regardless of age or comorbidities. However, treatment for hypertension still varies based on 
patient and provider preference (American Heart Association, 2017). Providers may remain 
weary over treating an elderly patient with multiple risk factors the same way they would treat 
a young adult with few risk factors who also has hypertension. Practice guidelines do not 
always reflect data from recent clinical trials, and provider skill level varies widely (American 
Heart Association, 2017; Kirk et al., 2017). Goals include reversing the increasing magnitude 
of heart disease through the modifiable risk factors of hypertension, high cholesterol, cigarette 
smoking, diabetes, exercise, stress management, and weight management (Office of Disease 
Prevention and Health Promotion, 2019).  
 Questionnaires asking teachers to rate their experience of stress at work typically 
indicate that about a quarter of schoolteachers regard teaching as a `very or extremely stressful' 
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job (Kyriacou, 2001). It has been well documented that teachers have a higher prevalence of 
anxiety, hypertension, headaches, psychosomatic disorders and cardiovascular diseases 
compared with other workers (Yang et al., 2009). Targeting one or more of these risk factors 
would make a significant impact on the $320 billion spent yearly on cardiovascular disease 
(Office of Disease Prevention and Health Promotion, 2019). In addition to being financially 
responsible, improvements in blood pressure would lead to decreased morbidity and mortality, 
and improved quality of life (Office of Disease Prevention and Health Promotion, 2019). In a 
recent meta-analysis of randomized controlled trials, there was a 20% reduction in CVD 
events, 27% reduction in strokes, and 28% reduction in heart failure for every 10 mm Hg 
decrease in systolic blood pressure (Ghazi & Oparil, 2018). This means that even slight 
decreases in blood pressure can make a large difference. When authority figures model healthy 
behaviors, such as weight management and mindfulness, their peers are more likely to mirror 
their good habits.  
Internal Evidence 
 A school district in rural Arizona has found harm reduction to be a significant problem 
worth addressing. Individuals diagnosed with cardiovascular risk factors are very diverse, with 
a larger percentage of Hispanics. Hispanic Americans and African Americans have 
disproportionate rates of uncontrolled hypertension compared to Caucasians (American Heart 
Association, 2019; Davidson et al., 2015; Office of Disease Prevention and Health Promotion, 
2019). Often, the patients seen in this setting are on AHCCCS, Medicare, or uninsured. The 
school is in a rural area, where public transportation is virtually nonexistent. Large grocery 
stores are present, but healthier food choices are infrequent and unaffordable to most of these 
clients. Barriers to cardiovascular disease include transportation to doctors, grocery stores, and 
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pharmacies. Poor dietary choices, lack of exercise, and medication nonadherence are frequent 
concerns noted by key stakeholders. Language barrier, poor compliance with the plan of care, 
and low socioeconomic status are other challenges with this population. The sweltering heat, 
along with lack of safe recreational facilities and reliable transportation are frequent concerns. 
The school principal is interested in implementing an intervention that could positively impact 
the teachers through positive learned behaviors and could decrease cardiovascular risk factors.  
PICOT 
 In adults with hypertension, how do brief harm reduction strategies (motivational 
interviewing, dietary and exercise guidance) compared to standard of care affect lifestyle 
behaviors and risk reduction over 3 months?    
Search Strategy 
Databases 
 An exhaustive search was conducted using the following academic data bases: 
PubMed, Wiley Online, EBSCO, CINAHL, Cochrane, PsycINFO, and Google Scholar for 
grey literature. Initial database searches in the Cochrane database yielded 104,810 results, but 
the 7th revision of search terms narrowed the results down to 2,342. An EBSCO search gave 
90,905 hits, but by the 8th revision there were 66 relevant articles. One of the PubMed searches 
resulted in 8125 initial hits and ended in 61 results, which was much easier to navigate and 
yielded more appropriate results. The final PubMed search yielded only 27 articles, but they 
were the most relevant.  
Search Terms 
 A keyword search was first conducted to assess the utility of the PICOT question. 
Later, a subject headings search was performed, using MeSH terms delineated from the 
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keyword search. The search terms used included motivational interviewing, directive 
counseling, patient education, educators, teachers, behavior change, behavior modification, 
behavior intervention, lifestyle change, lifestyle intervention, lifestyle modification, lifestyle 
counseling, self-management coaching, drugs, medication adherence, blood pressure, high 
blood pressure, cardiovascular disease, risk factors, hypertension, rural or underserved 
populations, low income, medication, medication management, pharmacology, 
pharmacotherapy, prescription, North America, Canada, or United States, decrease blood 
pressure, improve blood pressure, English, last 5 years, published in the last 5 years.  
Mesh Terms 
 Mesh terms included Motivational Interviewing, Directive Counseling, Patient 
Education as Topic, Lifestyle, and Hypertension. Changing key terms and limiting or 
expanding the search to find the most relevant results was necessary and needed to be adjusted 
with each database search. Guidelines reflect the probability that factors such as high blood 
pressure are affected by genetics, and therefore studies that focused on populations similar to my 
own were preferentially selected. 
Inclusion and Exclusion Criteria 
 Exclusion criteria were sometimes limited to data from other countries, as the patient 
population may have differed too greatly. Another limiter was age of study, which was focused 
on the last 5 to 10 years, unless they were guidelines or imperative articles. Generally, 
inclusion criteria for most studies consisted of a certain age range, usually middle-aged to older 
adults, without other chronic conditions that could confound the results, such as dementia, 
congestive heart failure, or COPD. In most cases, the patients must be able to provide informed 
consent. Some studies limited subjects to those on one antihypertensive medication, while 
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others allowed for polypharmacy subjects. Preference was given to studies that focused on 
rural, low-income, or disadvantaged populations, but this was not part of the inclusion criteria. 
Gender, education, occupation, religion, and other sociodemographic factors were often 
mentioned but not listed as inclusion or exclusion criteria.  
Critical Appraisal and Synthesis of Evidence 
 A systematic review of 10 randomized controlled trials was conducted. As the highest 
level of evidence, these studies should guide further practice (Melnyk & Fineout-Overholt, 
2015). All of the articles focused on reduction of cardiovascular disease risk factors, such as 
hypertension. Some articles also looked at stroke prevention and hyperlipidemia (Barker-Collo 
et al., 2015; Hedegaard et al., 2015). Most of the studies used motivational interviewing 
techniques to illicit medication adherence. Although not all of the studies yielded statistically 
significant results for every variable they measured, the findings were still clinically significant 
because there was little risk to the patient and hypertension management is multifactorial. Few 
studies referred to cost involved, though providing basic education at every patient encounter 
should be the expectation in healthcare. An intent-to-treat approach was utilized, and thus the 
controls were still given standard care, which is likely why many factors were not found to have 
statistical significance between the intervention and control groups (Barker-Collo et al., 2015; 
Boutin-Foster et al., 2016; Carter et al., 2015; Schoenthaler et al., 2015). While most of the 
research was completed in the primary care setting, some research was carried out in other areas, 
such as inpatient settings by pharmacists (Stewart et al., 2014). Generally, the data suggests that 
a culturally appropriate intervention that focuses on harm reduction through education and 
support will at least be mildly successful. Some of the articles reached a generalizable 
population, while others concentrated on a very rural or underserved population, which was my 
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focus (Appendix B). Motivational interviewing (MI) was used widely across the studies as an 
intervention, because it is useful in helping to change lifestyle behaviors among many chronic 
diseases (Barker-Collo et al., 2015; Boutin-Foster et al., 2016; Friedberg et al., 2015; Ogedegbe 
et al., 2008). However, there was great variability in how the MI was delivered and whether or 
not other factors were controlled for. For instance, some MI was performed as a standardized 
process in clinic settings, while other researchers executed MI over the telephone (Barker-Collo 
et al., 2015; Boutin-Foster et al., 2016; Carter et al., 2015; Friedberg et al., 2015; Hedegaard et 
al., 2015). Timelines for implementing the intervention varied by study. Yet another variable 
scrutinized was perceived quality of life, and the ability to manage one’s own health (Boutin-
Foster et al., 2016). In these studies, MI was a good tool to help the patients feel supported and 
competent in positively changing their behaviors.  
 While MI has inconsistent results in regard to behavior change associated with 
cardiovascular disease, many argue that this method is beneficial due to the knowledge 
imparted and low risk posed to the participants. Many studies support standard patient 
education delivered in a culturally sensitive manner for optimal effect. In this rural community 
of educators, an informational program tailored to the needs of the population was delivered 
based on the findings of numerous successful outcomes in the literature review mentioned 
above. This intervention was chosen based on previous models where low income, rural 
participants were successful in achieving risk reduction measures, such as lowering blood 
pressure.  
Theoretical Framework 
 Bandura’s Social Cognitive Theory (Appendix C) was chosen as it has been widely 
used to illicit behavior change across disciplines. The theory implies that a person’s individual 
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characteristics may be shaped by interactions, the environment, or by observing others 
(Bandura’s Social Cognitive Theory, 2003). Improving self-efficacy is a hallmark of Bandura’s 
Social Cognitive Theory (2003). Through mastery, social modeling, social persuasion, and 
physical and emotional states, we can work to develop efficacy (Bandura’s Social Cognitive 
Theory, 2003). Those who are able to develop self-efficacy are more likely to believe they 
have the power to make desirable changes through their own actions (Bandura’s Social 
Cognitive Theory, 2003). Efficacy is a personal judgement of one’s own capability and is not 
to be confused with self-esteem (Bandura’s Social Cognitive Theory, 2003). Social cognitive 
theory describes how humans acquire information and competencies, along with what 
motivates and regulates their behavior (Bandura, 2012). It also helps to explain how modeling 
the behaviors we see in others, good or bad, shape our subjective reality (Bandura, 2012). It 
makes sense that culture, motivation, pressure, and influence on our thoughts and actions might 
cause us to react or fail to react. The way in which we perceive our surroundings and our 
emotions are other strong pulls to action, or lack thereof. If we can understand what motivates 
our patients, what inspires them, and how-to best model that behavior for them, we might find 
that less time and effort will be required to evoke the change we seek. Theories may be used to 
guide the study and are particularly useful for describing social norms (Melnyk & Fineout-
Overholt, 2015). Theory is used to inform practice, and there exists a continual relationship 
between theory, research, and practice (Moran, Burson, & Conrad, 2017). They are particularly 
relevant when describing social phenomena, and when studying population health patterns and 
evaluating interventions (Moran, Burson, & Conrad, 2017). 
Evidence Based Practice Model 
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 The JBI Model was selected for its utility to the PICOT question.  This model 
(Appendix D) has been used when sensitivity to a particular population is concerned (Pearson, 
Wiechula, & Lockwood, 2005). This model works nicely with the Social Cognitive Theory as 
it focuses on patient and provider knowledge and experience in clinical decision making 
(Pearson, Wiechula, & Lockwood, 2005). Utilizing the resources guided by the JBI Model for 
patients in this rural area would be unique and welcomed by the populace, who may not want 
to adhere to traditional methods of cardiovascular risk reduction. As providers, we could show 
empathy and compassion by offering resources and information that is culturally sensitive and 
does not fit with the traditional medicine model. Serving as an information source or linking 
clients to healthy foods and affordable healthcare is vital. This model requires engaged 
practitioners, who are motivated to make a difference through various means. They may need 
to rely on community stakeholders and advocate for their clients, since evidence-based 
healthcare may not always align with the goals in the community served (Pearson, Wiechula, 
& Lockwood, 2005). Healthcare evidence generation, evidence synthesis, knowledge transfer, 
and evidence utilization are components of the JBI model (Pearson, Wiechula, & Lockwood, 
2005). Since the needs of the population are beyond that of any single health profession, 
advanced practice nurses will need to be astute to the barriers associated with wellness and 
focus on interprofessional collaboration to meet the needs of the people (Zaccagnini & White, 
2017).  Collaborating as healthcare providers with educators in the community can potentially 
make a larger impact than targeting individual patients who already have disease. The JBI 
model was utilized to develop a unique and tailored intervention that focused on the needs and 
desires of the population and site. Key stakeholders were involved in project implementation 
and delivery to enhance participation and limit attrition.  
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Methods 
IRB Approval 
 The project was approved by the Buckeye Preschool Principal and the Arizona State 
University (ASU) IRB. 
Ethical considerations and human subject protection 
 No personal identifying information was collected from participants. Only the principal 
investigator and co-investigator (ASU faculty) had access to the data. Participants were asked 
to give informed consent during the enrollment period. Agreement to participate in the project 
and complete the surveys was considered as the consent to access the participants responses. 
 
Budget 
 All costs associated with this intervention have been the responsibility of the primary 
investigator. No funding was received to develop or complete the project.  
Risk to participants 
 There is no known risk to participants who chose to complete the program. 
Population and setting 
 Buckeye Preschool District staff over the age of 18 who were willing and able to give 
consent were invited to participate. No effort was made to identify special populations for 
either inclusion or exclusion. Teachers and educators were targeted for recruitment. 
Participants must be able to read and write in English. Exclusion criteria include age less than 
18 years, non-English speaking, and not able or willing to provide consent. 
Project description and timeline 
MOTIVATIONAL INTERVIEWING IMPACT ON CVD     15 
 Participants were recruited beginning October 14, 2019 via email and word of mouth 
from the Buckeye Preschool Principal. Upon informed consent, The Quality of Well-being 
scale- self-administered version (QWB-SA) and the General Self-Efficacy Scale were both 
used as pre-intervention surveys to gain an understanding of baseline health assessment. 
Participants had 12 weeks to complete the online educational program and contact the 
investigator with any questions. Upon completion and at their leisure, participants again took 
the (QWB-SA) and the General Self-Efficacy Scales to assess for project impact. 
Data analysis 
  Data was stored and analyzed in Microsoft Excel and Intellectus Statistics®. Surveys 
were collected online via Survey Monkey. Descriptive statistics were used to analyze pre and 
post survey responses to the QWB-SA and the General Self-Efficacy Scale. A two-tailed 
Wilcoxon signed rank test was conducted to examine whether there was a significant 
difference between the pre and post survey results. The Wilcoxon Signed Rank test is a non-
parametric test used to assess for significant differences between two scale or ordinal variables 
that can be matched. Typically, the variables are matched by time (such as pretest vs. posttest), 
but the data can also be matched by other characteristics (such as husband vs. wife). This test 
ranks the pairs of scores by the magnitude of the differences between each matched pair, then 
sums the signed ranks to compute the V statistic (Intellectus Statistics, 2020). The V statistic is 
then used to compute z, which in turn is used to compute the p-value, the significance level 
(Intellectus Statistics, 2020). A significant result for this test suggests that the two matched 
variables are reliably different from each other. The Wilcoxon Signed Rank test assumes that 
the variables under investigation are scale or ordinal level. A p value < 0.05 was used for 
statistical significance.  
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Results 
 Descriptive Statistics were used to analyze the following 10 variables for likeness. The 
following results section details both the PRE and POST variables of Table 2 (Appendix F) 
and Table 3 (Appendix G) by pairing the matching variables together (e.g., Excessive worry 
and anxiety PRE and POST). The observations for PRE excessive worry or anxiety had an 
average of 24.90 (SD = 133.18, SEM = 24.31, Min = 0.00, Max = 730.00, Skewness = 5.20, 
Kurtosis = 25.03).The observations for POST excessive worry or anxiety had an average of 
26.46 (SD = 137.88, SEM = 26.06, Min = 0.00, Max = 730.00, Skewness = 5.00, Kurtosis = 
23.04). The observations for PRE feeling upset, downhearted or blue had an average of 0.47 
(SD = 1.01, SEM = 0.18, Min = 0.00, Max = 3.00, Skewness = 1.84, Kurtosis = 1.69). The 
observations for POST feeling upset, downhearted or blue had an average of 0.46 (SD = 
0.96, SEM = 0.18, Min = 0.00, Max = 3.00, Skewness = 1.76, Kurtosis = 1.51). The 
observations for PRE frustration irritation or close to losing your temper had an average of 
0.63 (SD = 1.27, SEM = 0.23, Min = 0.00, Max = 6.00, Skewness = 2.86, Kurtosis = 8.85). The 
observations for POST frustration irritation or close to losing your temper had an average of 
0.32 (SD = 0.72, SEM = 0.14, Min = 0.00, Max = 3.00, Skewness = 2.44, Kurtosis = 5.51).  
When the skewness is greater than 2 in absolute value, the variable is considered to be 
asymmetrical about its mean. When the kurtosis is greater than or equal to 3, then the variable's 
distribution is markedly different than a normal distribution in its tendency to produce outliers 
(Westfall & Henning, 2013). The summary statistics can be found in Table 2 (Appendix F) and 
Table 3 (Appendix G). 
MOTIVATIONAL INTERVIEWING IMPACT ON CVD     17 
 Over 40 variables were analyzed, and none were found to be statistically significant. 
However, the findings illustrated the need for further interventions, as many subjects reported 
baseline pain, fatigue, and other emotional and physical concerns. Therefore, one could argue 
that the results were clinically significant and should be evaluated further to improve physical 
and mental wellbeing.  
Impact of project 
 The principal investigator was pleased to experience the cooperation and support of the 
local school district and educators. Overall, the participants had a fair amount of generalized 
complaints and the intervention was affordable and accessible. A program such as this that 
focuses on enhancing knowledge and holistic health is easy to implement and easily 
sustainable. It is unknown at this time if the project intervention, or similar methods, will be 
sustained, but there have been some talks about expanding a program such as this. Due to 
Covid-19, the school districts will be closed for an undisclosed period of time and are not 
available for follow up discussions.  
Discussion 
Summary 
 Risk reduction of cardiovascular events is a concern locally, nationally, and globally. In 
order to combat the negative effects of cardiovascular disease, a multidisciplinary team approach 
is necessary to deliver care in a consistent and culturally competent manner. If we want to reduce 
risk of cardiovascular disease, we need to decrease the dependence on medicine and focus our 
interventions toward lifestyle changes. By educating teachers, who are in a unique position to 
impart behavioral interventions, we may not only be reaching them in a sustainable and non-
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threatening way, but we may also affect the wellbeing of their children and parents, as they gain 
the skills they need to improve their health status more consistently. By holistically treating our 
communities and providing them with the resources they need to make smart decisions, we 
reinforce healthy behaviors for generations. Any efforts to reach this population will have 
lasting effects on the way they raise their young and care for their elderly. Simple efforts, such 
as promoting fresh foods and providing ideas for exercise regimens, can help families make 
choices that significantly reduce harm in the long run. 
Limitations 
 Targeting harm reduction is multifaceted and requires interprofessional collaboration 
and community support. It also necessitates the need for compassionate, engaged health 
professionals who can serve as innovators in healthcare delivery. Numerous stakeholders in 
town suggest that, while there are resources, there are either not enough or they are not readily 
available to the people. Risk reduction for cardiovascular diseases encompasses many aspects 
of care and is difficult to achieve in disadvantaged communities. Perhaps, if patients had 
increased access to education, resources and coaching, they may develop improved self-
efficacy and self-management tools. If they were competent in how to incorporate a nutritious 
diet and moderate exercise into their lifestyles, the need would be less for medications, and the 
clients would understand how diseases like hypertension affect their risk for debilitating 
conditions such as heart attack or stroke. Simple interventions, such as limiting sodium intake, 
can significantly improve cardiovascular measures, but have failed to do so (Office of Disease 
Prevention and Health Promotion, 2019). This suggests that despite efforts, cardiovascular risk 
reduction is still a problem, and widescale interventions have not always been met with 
success.  
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Recommendations 
 This rural community is in need of comprehensive healthcare. Motivational 
interviewing and self-management are gaining traction in chronic disease management, 
because clients need the education and skills necessary to make lasting behavioral changes. 
These tools guide practitioners through a method of teaching in a manner that is sensitive yet 
informative. Through risk reduction via lifestyle changes and increasing adherence to the 
treatment plan, multiple studies have suggested statistically significant changes in numerous 
metrics. Positive results were seen with community-based interventions in similar populations 
(Ogedegbe et al., 2008). Treating this rural community of educators with a unique and tailored 
approach to risk reduction may yield greater impacts in the field of chronic disease 
management and may improve workplace dynamics and decrease sick days. It is therefore 
suggested that this topic be further studied.  
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(Hedegaard 
et al., 2015). 
MA in 
patients with 
HTN: a 
RCT.   
 
Country: 
Denmark 
 
Funding: 
Funded by 
unrestricted 
grants from 
The 
Hospitals 
Pharmacies’ 
and Amgros’ 
Research 
Developmen
-t FDN and 
The Actavis 
FDN. 
  
NS (Self-Care 
Theory) 
Design: RCT 
 
Purpose:  A 
randomized 
trial was 
performed to 
investigate 
the 
effectiveness 
of a 
multifaceted 
PH IN in a 
HS to 
improve MA 
in 
hypertensive 
pts. MI was a 
key element 
of the IN. 
 
 
N- 532 
n– 516 
IG – 231 
CG-285 
Demographics: 
M age – 62 yrs 
m/f- 60/40% 
Edu: NS 
 
Setting: Odense 
University 
Hospital, 
Denmark. Dec. 
2012-July 2013. 3 
outpatient clinics.  
 
Inclusion: Pts 
with HTN from 1 
cardiology and 2 
endocrinology 
OC. 18 yrs. or 
older, RX for at 
least 1 AA. 
Exclusion: Pts 
IV: adherence. The IG 
received usual care 
and a PH IN 
consisting of 3 
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focused on identifying 
drug-related problems 
for antihypertensive 
or LC agents followed 
by advice to the PCP 
in charge; 2) a pt 
INTV; 3) 2 or more 
follow-up TC to the pt 
within the first 6 mos 
after inclusion. 
 
 
DV1: LC agents 
DV2: AA 
DV3: LC agents 
 
IV1: The primary 
outcome was overall 
adherence to AA and 
LC agents 12 months 
DRAW, MAQ, 
SBP, DBP 
 
Median 
difference 
estimate was 
derived from 
the Hodges- 
Lehmann 
estimate, 
mixed- 
effect linear 
regression 
model, 
Kaplan-
Meier curve, 
Cox 
proportional 
hazard 
model, CI, 
FE, unpaired 
t test, 
Wilcoxon-
Mann 
Whitney 2- 
sided test, 
EpiData 
version 3.1, 
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 IG – 0.93 
(0.82-0.99) 
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(0.76-0.98) 
p value - 0.02 
 
DV2 
IG – 0.95 
CG- 0.94 
p value - 0.23 
 
DV3 
IG- 0.97 
CG-0.89 
p value-0.02 
 
Cohen’s D= 
0.11 (small) 
 
 
Level of Evidence: LOE II  
 
Strengths: Strong methodology, 
reliable instruments, faster medical 
assessment, researcher was blinded 
when assessing outcomes. 
 
Weaknesses: educational levels NS, 
and exclusion of pts outside 
Denmark region. SS. More pts than 
expected chose not to participate. Pts 
had MC, which may have affected 
their MPR. F/u measurements were 
missing for 26% of the cohort. PH 
and PCPs were not blinded to 
allocation. 
 
Conclusions: A multifaceted PH IN 
in a HS led to a sustained 
improvement in MA for pts with 
HTN. 
 
 
Feasibility: The IN had no 
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care physician, PCMO-primary care medical offices, PH – Pharmacist, PI- psychiatric illness, Pt – Patient, RCT – Randomized Controlled Trial, RA – renin-angiotensin agents, RD- renal disease, RF – renal failure, Rx – 
Prescription,  SAS - Statistical Analysis Software, SBP- systolic blood pressure, SC – Self-care, SD – Standard deviation, SE-self-efficacy, SPSS - Statistical Package for the Social Sciences, SS - # of study sites, STS- Structured 
telephone support, Sys – systolic, TAU – Treatment as usual, TI – Terminal illness, TM – Telemonitoring,  TC – Telephone call, UC- usual care, U.S.- United States, WFFQ- Willett Food Frequency Questionnaire, X2 – Chi 
square, Yrs – years, NO- Number of 
Bias: 
Contaminati
-on bias 
(Excluded 
pts without 
an AA or 
those with 
more than 1 
AA, which 
is often 
standard of 
care).  
who lived in a 
CH, TI, MDP, 
MDHN, Pts 
residing outside of 
the Denmark 
region, or CogI. 
Attrition:  
21.05% 
after inclusion, 
reported as a 
continuous, as well as 
a binary outcome. 
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outcomes were 
composite MPR at 3, 
6, and 9 months, as 
well as adherence and 
persistence to D, CA, 
BB, RA, and LC 
agents, all at 12 
Stata version 
13 
significant impact on BP and 
secondary clinical outcomes. Should 
be studied further before applying to 
practice.  
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variable 2, DV3 – Dependent variable 3, DV4 - Dependent variable 4, DV5- Dependent variable 5, Edu – Education, EF – Ejection fraction, EMR-electronic medical record, EP – Exercise program, ES – Educational session, f – 
female, FDN- Foundation, FE – Fisher’s exact test, F/U – Follow Up, FQHC- federally qualified health center, GTET- greater than or equal to, HF-heart failure, HTN-  Hypertension,  HS – Hospital setting, IC-informed consent, 
IG - Intervention group, IG1 - Intervention group1, IG2 - Intervention group 2, IL - Inadequate literacy, IN-intervention, INTV- interview, IV – Independent variable, LC – Lipid control, LDL- low-density lipoprotein, LOE- 
level of evidence, MA – Medication adherence,  MAQ-medication adherence questionnaire,  M –Mean, MC – Multiple comorbidities, MDHN – Medication dispensed by Home Nurse, meds- medications, MEMS- Medication 
event monitoring system, MI – Motivational interviewing  mos.- months, MDP – medication dispensed by pharmacy, MMAS-Morisky medication adherence scale, Mos-months, MPR- Medication Possession Ratio Measure, MR 
– Medication review, N – Sample (population), n – Sample size (studies), NS – Not stated, NCP- non-complaint patients, OR – Odds ratio, PCG - Placebo call group, PCDI - Patient centered discharge instructions PCP – Primary 
care physician, PCMO-primary care medical offices, PH – Pharmacist, PI- psychiatric illness, Pt – Patient, RCT – Randomized Controlled Trial, RA – renin-angiotensin agents, RD- renal disease, RF – renal failure, Rx – 
Prescription,  SAS - Statistical Analysis Software, SBP- systolic blood pressure, SC – Self-care, SD – Standard deviation, SE-self-efficacy, SPSS - Statistical Package for the Social Sciences, SS - # of study sites, STS- Structured 
telephone support, Sys – systolic, TAU – Treatment as usual, TI – Terminal illness, TM – Telemonitoring,  TC – Telephone call, UC- usual care, U.S.- United States, WFFQ- Willett Food Frequency Questionnaire, X2 – Chi 
square, Yrs – years, NO- Number of 
(Alhalaiqa et 
al., 2012). 
AT for 
medication 
NCP with 
HTN: a RCT  
 
Country: 
UK 
 
Funding: 
Funded by a 
doctoral 
studentship 
grant from 
Philadelphia 
University, 
Jordan and 
the 
University 
of East 
Anglia, UK. 
The funders 
were not 
involved in 
the design or 
analysis of 
this study.  
 
Bias: 
Selection 
bias 
(Enrollment 
was done 
NS (cognitive 
and 
motivational 
interviewing 
techniques) 
Design: 
Parallel-
group single-
blind RCT 
 
Purpose: 
Primary 
outcome was 
to establish 
the efficacy 
of AT 
compared 
with TAU in 
reducing BP 
in NCP 
N=136  
IG:  68 
CG: 68 
Demographics: 
 M age- 53 yrs,  
f - 54% 
C – 67% 
smokers – 31% 
married- 76 % 
Setting: Patients 
were recruited 
from 3 general 
hospital outpatient 
clinics in Jordan 
 
Inclusion: Any 
HTN pt who 
visited one of 3 
clinics in Jordan 
from Aug. 2009- 
Jan. 2010, age 
18+, assessed as 
NCP by reviewers 
Exclusion: mental 
illness, HTN 
complications, 
DM, CHF, RF, 
other CD, or 
pregnancy. 
Attrition: 10 
(7.3%). 
IV1: Adherence 
(measured by pill 
counting) AT=7 one-
on-one sessions 
lasting 20 min. over 7 
wks. Measured at 
baseline and 11 wks 
after randomization. 
Calculated by 
dividing the # of pills 
not taken in a month 
by the total # of pills 
RX’d. 
 
DV1: SBP (over 140) 
measured at baseline 
and 11 wks after 
randomization 
 
DV2: DBP (over 90) 
measured at baseline 
and 11 wks after 
randomization 
 
DV3-(G-H) general 
harm, intrinsically 
harmful properties of 
meds 
 
DV4- (G-O) general 
overuse of meds by 
providers 
 
DV5- (G-B) general 
SBP, BAMQ, 
MMAS, mercury 
syphymomano-
meter measured 
twice on right 
upper arm of a 
seated patient 
who had been 
resting for over 
10 minutes 
(average of 2 
measurements 
was used) 
SD, alpha 
0.05, 80% 
power, 2-
tailed test of 
significance, 
5-point 
Likert-type 
scale, 
Rubin’s 
equations, 
analysis of 
covariance, 
logistic 
regression 
IV1- 37%  
                           
DV1- 23.4 
(95% CI: 
20.7, 26.2) 
IG – 97% 
CG – 71% 
p value - 0.01 
 
DV2 – 15.6 
(95% CI: 
13.2, 17.9) 
p value -0.01 
 
DV3- (G-
H:0.75, 
p<0.001) 
 
DV4- (G-O: -
0.31, 
p<0.001) 
DV5- (G-S: -
0.46, 
p<0.001) 
 
Cohen’s D= 
0.22 (small) 
 
Level of Evidence: LOE II 
 
Strengths: Analysts were blinded, 
computer generated randomized 
allocation to groups. Power analysis 
for sample size and economic 
analysis were performed; low 
attrition rate. BAMQ has established 
validity.  
 
Weaknesses: Assessment of 
potential applicants was stopped 
when sufficient numbers had been 
recruited to the study, TAU was not 
clearly defined. Short follow-up 
period (1 month). Pts knew they 
were being monitored. AT was 
delivered by only one person. 
Unknown if generalizable.  
 
Conclusions: AT improves MA for 
HTN 
 
Feasibility: Suggests AT for HTN is 
clinically important for use in 
practice and is likely to be cost-
effective.  
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Prescription,  SAS - Statistical Analysis Software, SBP- systolic blood pressure, SC – Self-care, SD – Standard deviation, SE-self-efficacy, SPSS - Statistical Package for the Social Sciences, SS - # of study sites, STS- Structured 
telephone support, Sys – systolic, TAU – Treatment as usual, TI – Terminal illness, TM – Telemonitoring,  TC – Telephone call, UC- usual care, U.S.- United States, WFFQ- Willett Food Frequency Questionnaire, X2 – Chi 
square, Yrs – years, NO- Number of 
after 
Randomizati
on). 
 
benefit, the 
intrinsically beneficial 
properties of meds 
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female, FDN- Foundation, FE – Fisher’s exact test, F/U – Follow Up, FQHC- federally qualified health center, GTET- greater than or equal to, HF-heart failure, HTN-  Hypertension,  HS – Hospital setting, IC-informed consent, 
IG - Intervention group, IG1 - Intervention group1, IG2 - Intervention group 2, IL - Inadequate literacy, IN-intervention, INTV- interview, IV – Independent variable, LC – Lipid control, LDL- low-density lipoprotein, LOE- 
level of evidence, MA – Medication adherence,  MAQ-medication adherence questionnaire,  M –Mean, MC – Multiple comorbidities, MDHN – Medication dispensed by Home Nurse, meds- medications, MEMS- Medication 
event monitoring system, MI – Motivational interviewing  mos.- months, MDP – medication dispensed by pharmacy, MMAS-Morisky medication adherence scale, Mos-months, MPR- Medication Possession Ratio Measure, MR 
– Medication review, N – Sample (population), n – Sample size (studies), NS – Not stated, NCP- non-complaint patients, OR – Odds ratio, PCG - Placebo call group, PCDI - Patient centered discharge instructions PCP – Primary 
care physician, PCMO-primary care medical offices, PH – Pharmacist, PI- psychiatric illness, Pt – Patient, RCT – Randomized Controlled Trial, RA – renin-angiotensin agents, RD- renal disease, RF – renal failure, Rx – 
Prescription,  SAS - Statistical Analysis Software, SBP- systolic blood pressure, SC – Self-care, SD – Standard deviation, SE-self-efficacy, SPSS - Statistical Package for the Social Sciences, SS - # of study sites, STS- Structured 
telephone support, Sys – systolic, TAU – Treatment as usual, TI – Terminal illness, TM – Telemonitoring,  TC – Telephone call, UC- usual care, U.S.- United States, WFFQ- Willett Food Frequency Questionnaire, X2 – Chi 
square, Yrs – years, NO- Number of 
(Ogedegbe 
et al., 2008). 
 
A practice-
based trial of 
MI and 
adherence in 
hypertensive 
African 
Americans.   
 
Funding: 
grants from 
the National 
Heart, Lung, 
and Blood 
Institute and 
the National 
Institutes of 
Health 
Bethesda, 
MD,  
 
Country: 
USA 
 
Bias: 
contamina-
tion 
 
Self-care 
model- NS 
This RCT 
tested the 
effect of a 
practice-
based MI 
counseling 
vs. UC on 
MA and bp in 
190 
hypertensive 
African 
Americans.  
N=190 
n-UC group 95 
n-intervention 
group 95 
M age: 54 years 
Demographics: 
88% women, 17% 
married, 77% high 
school or college 
education, over 
50% unemployed, 
recruited from 2 
community-based 
primary care 
practices in New 
York City (NY 
Presbyterian 
Hospital 
Ambulatory Care 
Network).  
 
Inclusion: age 
gtet 18, black or 
African American, 
able to provide 
written informed 
consent, 
diagnosed with 
htn (bp gtet 
140/90 or 130/80 
for those with DM 
or RD)  
Attrition: 13 
(6.84%) 
The primary outcome 
was adherence, 
measured by 
electronic pill 
monitors, secondary 
outcome was within-
patient change in 
office bp from 
baseline to 12 mos.  
MI-directive, patient-
centered counseling 
designed to motivate 
pts for change by 
helping them 
recognize and resolve 
the discrepancy 
between their 
behavior, personal 
goals, and values.  
MI group-received 
UC plus behavioral 
counseling about MA 
using MI techniques. 
30-40 min. of MI was 
received at 3, 6, 9, & 
12 mos.  
IV: UC group 
medication adherence 
DV1: MA in 
intervention group 
after 12 mos. 
DV2: sbp drop 12 
mos. after intervention 
DV3: dbp drop 12 
Charlson 
Comorbidity 
Index, MEMS, 
clinic bp 
readings, 
mercury 
sphygmomanome
ters,  
Randomizati
on, mixed-
effects 
regression 
models, 
Little’s 
MCAR 
IV: UC 
postinterventi
on 
adherence: 
43% 
(p=0.027) 
DV1: MI 
postinterventi
on 
adherence: 
57% 
(p=0.027) 
 
DV2: UC BP 
drop (t with 
145.1, df=-
2.26, 
P=0.026) vs 
MI group: (t 
with 150.5, 
df=-1.86, 
P=0.065).  
 
DV3: UC BP 
drop (t with 
151.2, df=-
2.61, P=0.01) 
vs MI group 
bp drop (t 
with 156.7, 
df= -0.73, 
P=0.003).  
 
Cohen’s D= 
LOE: 2 
 
Strengths: long duration of study 
(12 mos.), focused on low income, 
low education, and minority 
population (relevance to PICOT), 
practice-based intervention, 
although not statistically significant, 
was still clinically significant 
because it lowered bp 
measurements, low risk of adverse 
events to pts.  
 
Weaknesses: no blinding 
whatsoever, randomization was done 
after baseline assessment by the 
study statistician, missing data, 
limited generalizability, no account 
for intensity of bp treatment (med 
interventions) 
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AA – Antihypertensive agent, AfAm- African Americans, AI- adherence intervention, ANCOVA- analysis of covariance, AT – Adherence therapy, BB- beta-blockers, BP – Blood pressure,  BAMQ – Beliefs about medications 
questionnaire, CA- Calcium antagonists, CBMC-community based medical center, CD- chronic disease, CKD- chronic kidney disease, CG – Control group, CHF- congestive heart failure, CI – Confidence interval, CogI – 
Cognitively impaired, CS – Community setting, CVD-cardiovascular disease, D – Diuretics, DBP – diastolic blood pressure, DM- diabetic, DRAW- drug adherence work-up tool, DV1 – Dependent variable 1, DV2 – Dependent 
variable 2, DV3 – Dependent variable 3, DV4 - Dependent variable 4, DV5- Dependent variable 5, Edu – Education, EF – Ejection fraction, EMR-electronic medical record, EP – Exercise program, ES – Educational session, f – 
female, FDN- Foundation, FE – Fisher’s exact test, F/U – Follow Up, FQHC- federally qualified health center, GTET- greater than or equal to, HF-heart failure, HTN-  Hypertension,  HS – Hospital setting, IC-informed consent, 
IG - Intervention group, IG1 - Intervention group1, IG2 - Intervention group 2, IL - Inadequate literacy, IN-intervention, INTV- interview, IV – Independent variable, LC – Lipid control, LDL- low-density lipoprotein, LOE- 
level of evidence, MA – Medication adherence,  MAQ-medication adherence questionnaire,  M –Mean, MC – Multiple comorbidities, MDHN – Medication dispensed by Home Nurse, meds- medications, MEMS- Medication 
event monitoring system, MI – Motivational interviewing  mos.- months, MDP – medication dispensed by pharmacy, MMAS-Morisky medication adherence scale, Mos-months, MPR- Medication Possession Ratio Measure, MR 
– Medication review, N – Sample (population), n – Sample size (studies), NS – Not stated, NCP- non-complaint patients, OR – Odds ratio, PCG - Placebo call group, PCDI - Patient centered discharge instructions PCP – Primary 
care physician, PCMO-primary care medical offices, PH – Pharmacist, PI- psychiatric illness, Pt – Patient, RCT – Randomized Controlled Trial, RA – renin-angiotensin agents, RD- renal disease, RF – renal failure, Rx – 
Prescription,  SAS - Statistical Analysis Software, SBP- systolic blood pressure, SC – Self-care, SD – Standard deviation, SE-self-efficacy, SPSS - Statistical Package for the Social Sciences, SS - # of study sites, STS- Structured 
telephone support, Sys – systolic, TAU – Treatment as usual, TI – Terminal illness, TM – Telemonitoring,  TC – Telephone call, UC- usual care, U.S.- United States, WFFQ- Willett Food Frequency Questionnaire, X2 – Chi 
square, Yrs – years, NO- Number of 
Exclusion: ns mos. after intervention 0.07=small 
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AA – Antihypertensive agent, AfAm- African Americans, AI- adherence intervention, ANCOVA- analysis of covariance, AT – Adherence therapy, BB- beta-blockers, BP – Blood pressure,  BAMQ – Beliefs about medications 
questionnaire, CA- Calcium antagonists, CBMC-community based medical center, CD- chronic disease, CKD- chronic kidney disease, CG – Control group, CHF- congestive heart failure, CI – Confidence interval, CogI – 
Cognitively impaired, CS – Community setting, CVD-cardiovascular disease, D – Diuretics, DBP – diastolic blood pressure, DM- diabetic, DRAW- drug adherence work-up tool, DV1 – Dependent variable 1, DV2 – Dependent 
variable 2, DV3 – Dependent variable 3, DV4 - Dependent variable 4, DV5- Dependent variable 5, Edu – Education, EF – Ejection fraction, EMR-electronic medical record, EP – Exercise program, ES – Educational session, f – 
female, FDN- Foundation, FE – Fisher’s exact test, F/U – Follow Up, FQHC- federally qualified health center, GTET- greater than or equal to, HF-heart failure, HTN-  Hypertension,  HS – Hospital setting, IC-informed consent, 
IG - Intervention group, IG1 - Intervention group1, IG2 - Intervention group 2, IL - Inadequate literacy, IN-intervention, INTV- interview, IV – Independent variable, LC – Lipid control, LDL- low-density lipoprotein, LOE- 
level of evidence, MA – Medication adherence,  MAQ-medication adherence questionnaire,  M –Mean, MC – Multiple comorbidities, MDHN – Medication dispensed by Home Nurse, meds- medications, MEMS- Medication 
event monitoring system, MI – Motivational interviewing  mos.- months, MDP – medication dispensed by pharmacy, MMAS-Morisky medication adherence scale, Mos-months, MPR- Medication Possession Ratio Measure, MR 
– Medication review, N – Sample (population), n – Sample size (studies), NS – Not stated, NCP- non-complaint patients, OR – Odds ratio, PCG - Placebo call group, PCDI - Patient centered discharge instructions PCP – Primary 
care physician, PCMO-primary care medical offices, PH – Pharmacist, PI- psychiatric illness, Pt – Patient, RCT – Randomized Controlled Trial, RA – renin-angiotensin agents, RD- renal disease, RF – renal failure, Rx – 
Prescription,  SAS - Statistical Analysis Software, SBP- systolic blood pressure, SC – Self-care, SD – Standard deviation, SE-self-efficacy, SPSS - Statistical Package for the Social Sciences, SS - # of study sites, STS- Structured 
telephone support, Sys – systolic, TAU – Treatment as usual, TI – Terminal illness, TM – Telemonitoring,  TC – Telephone call, UC- usual care, U.S.- United States, WFFQ- Willett Food Frequency Questionnaire, X2 – Chi 
square, Yrs – years, NO- Number of 
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Effectivenes
s of a 
tailored 
behavioral 
intervention 
to improve 
hypertension 
control: 
Primary 
outcomes of 
a 
randomized 
controlled 
trial. 
Funded by 
the Dept. of 
Veterans 
Affairs 
Health 
Services 
Research 
and 
Developmen
t Service 
Research 
Career 
Developmen
Transtheoretic
al model- as 
stated 
3-arm parallel 
RCT to 
evaluate 
whether a 
telephone-
delivered, 
behavioral 
stage-
matched 
intervention 
would lead to 
better bp 
control than 
UC in pts 
with 
uncontrolled 
bp.  
N=533 
n=SMI group 176 
n= UC group 177 
n=HEI group 180 
Inclusion: had 
HTN, on AA for 6 
mos, HTN was 
uncontrolled, able 
to provide 
informed consent 
Exclusion: CVD, 
HF stage 3 or 4, 
severe PI, AIDS, 
Tuberculosis, 
lupus, end-stage 
renal failure, less 
than 1-year life 
expectancy, lack 
of telephone, 
inability to follow 
study protocol, 
major surgery in 
last 3 mos., those 
not available for 
f/u, unable to 
provide consent, 
those temporarily 
in the area 
IV: Uncontrolled 
HTN- sbp gtet 130 or 
diastolic bp gtet 80 in 
DM or CKD, or sbp 
gtet 140 or dbp gtet 90 
in all others at the 
time of study. 
DV1: SMI- 
behavioral stage-
matched intervention 
DV2: HEI-
nontailored health 
education intervention 
DV3: UC group- 
received standard 
information about htn 
but no counseling 
DV4: MA- self-report 
of taking bp meds as 
prescribed for gtet 6 
days/week.  
Omron HEM 
907XL 
automated bp 
machine was 
used on the 
patients right 
upper arm 6x, 
cuff was placed 
1” above the 
crook of the 
elbow. Height 
and weight were 
also measured, 
and arm 
circumference 
was measured if 
there was any 
question to the 
size of the cuff.  
Computer 
generated 
random 
assignments 
to groups, 
telephone 
counseling 
for 6 mos., 
computer-
based 
intervention 
model for 
SMI group, 
MMAS, 
WFFQ, 
dietary 
approaches 
to stop htn 
score, 
Pearson X2, 
Rao-Scott 
X2, 
Bonferroni 
adjustment, 
logistic 
regression, 
SAS version 
9.2, 2-sided 
P values 
IV1: Bp 
control at 6 
mos.: 
DV1: SMI: 
64.6 
(p<0.001), 
DV2: HEI: 
54.3 (0.108), 
DV3: UC: 
45.8 
(p<0.05).  
SBP at 6 
mos: (95% 
CI) 
DV1:SMI: 
131.2 (129.1, 
133.3) SMI 
vs UC p = 
0.009 
DV2:HEI: 
131.8 (129.9, 
133.7) HEI 
vs UC 
p=0.047 
DV3:UC: 
134.7 (132.7-
136.7)  
IV:Change 
in 
proportion 
LOE: 2 
Weaknesses: used additional 
information other than AHA 
educational materials for HEI group, 
so information is not easily 
generalizable and reproducible, 
unable to judge quality of material 
as it is not standardized information. 
The study was not powered to test 
between the 2 active intervention 
arms. Many participants withdrew 
between enrollment period and first 
study visit, and also post-baseline 
(n=172). 
Strengths: relevance to the PICOT 
question, ease of use, randomization, 
baseline bp was similar among 
groups, mean of 6 bp measurements, 
low risk of adverse events to pts., 
reduced costs and increased 
scalability due to no in-person 
contact, ease of feasibility 
MOTIVATIONAL INTERVIEWING IMPACT ON CVD          33 
AA – Antihypertensive agent, AfAm- African Americans, AI- adherence intervention, ANCOVA- analysis of covariance, AT – Adherence therapy, BB- beta-blockers, BP – Blood pressure,  BAMQ – Beliefs about medications 
questionnaire, CA- Calcium antagonists, CBMC-community based medical center, CD- chronic disease, CKD- chronic kidney disease, CG – Control group, CHF- congestive heart failure, CI – Confidence interval, CogI – 
Cognitively impaired, CS – Community setting, CVD-cardiovascular disease, D – Diuretics, DBP – diastolic blood pressure, DM- diabetic, DRAW- drug adherence work-up tool, DV1 – Dependent variable 1, DV2 – Dependent 
variable 2, DV3 – Dependent variable 3, DV4 - Dependent variable 4, DV5- Dependent variable 5, Edu – Education, EF – Ejection fraction, EMR-electronic medical record, EP – Exercise program, ES – Educational session, f – 
female, FDN- Foundation, FE – Fisher’s exact test, F/U – Follow Up, FQHC- federally qualified health center, GTET- greater than or equal to, HF-heart failure, HTN-  Hypertension,  HS – Hospital setting, IC-informed consent, 
IG - Intervention group, IG1 - Intervention group1, IG2 - Intervention group 2, IL - Inadequate literacy, IN-intervention, INTV- interview, IV – Independent variable, LC – Lipid control, LDL- low-density lipoprotein, LOE- 
level of evidence, MA – Medication adherence,  MAQ-medication adherence questionnaire,  M –Mean, MC – Multiple comorbidities, MDHN – Medication dispensed by Home Nurse, meds- medications, MEMS- Medication 
event monitoring system, MI – Motivational interviewing  mos.- months, MDP – medication dispensed by pharmacy, MMAS-Morisky medication adherence scale, Mos-months, MPR- Medication Possession Ratio Measure, MR 
– Medication review, N – Sample (population), n – Sample size (studies), NS – Not stated, NCP- non-complaint patients, OR – Odds ratio, PCG - Placebo call group, PCDI - Patient centered discharge instructions PCP – Primary 
care physician, PCMO-primary care medical offices, PH – Pharmacist, PI- psychiatric illness, Pt – Patient, RCT – Randomized Controlled Trial, RA – renin-angiotensin agents, RD- renal disease, RF – renal failure, Rx – 
Prescription,  SAS - Statistical Analysis Software, SBP- systolic blood pressure, SC – Self-care, SD – Standard deviation, SE-self-efficacy, SPSS - Statistical Package for the Social Sciences, SS - # of study sites, STS- Structured 
telephone support, Sys – systolic, TAU – Treatment as usual, TI – Terminal illness, TM – Telemonitoring,  TC – Telephone call, UC- usual care, U.S.- United States, WFFQ- Willett Food Frequency Questionnaire, X2 – Chi 
square, Yrs – years, NO- Number of 
t Award. No 
disclosures 
reported. 
U.S. 
of bp under 
control from 
baseline to 6 
mos, %: 
DV1:SMI: 
19.7 (SMI vs 
UC 
p=0.0004) 
DV2: HEI: 
11.8 (HEI vs 
UC p=0.051), 
DV3: UC: 
1.9 
Change in 
sbp from 
baseline to 6 
mos.  
DV1: SMI: -
4.7 (-6.9, -
2.5) (SMI vs 
UC p=0.007) 
DV2: HEI: -
5.4 (-8.5,-
2.3) (HEI vs 
UC p=0.009) 
DV3: UC: -
2.7 (-5,-4).  
DV4: 
Medications 
(proportion 
% in action 
or 
maintenance 
at 6 mos.)  
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AA – Antihypertensive agent, AfAm- African Americans, AI- adherence intervention, ANCOVA- analysis of covariance, AT – Adherence therapy, BB- beta-blockers, BP – Blood pressure,  BAMQ – Beliefs about medications 
questionnaire, CA- Calcium antagonists, CBMC-community based medical center, CD- chronic disease, CKD- chronic kidney disease, CG – Control group, CHF- congestive heart failure, CI – Confidence interval, CogI – 
Cognitively impaired, CS – Community setting, CVD-cardiovascular disease, D – Diuretics, DBP – diastolic blood pressure, DM- diabetic, DRAW- drug adherence work-up tool, DV1 – Dependent variable 1, DV2 – Dependent 
variable 2, DV3 – Dependent variable 3, DV4 - Dependent variable 4, DV5- Dependent variable 5, Edu – Education, EF – Ejection fraction, EMR-electronic medical record, EP – Exercise program, ES – Educational session, f – 
female, FDN- Foundation, FE – Fisher’s exact test, F/U – Follow Up, FQHC- federally qualified health center, GTET- greater than or equal to, HF-heart failure, HTN-  Hypertension,  HS – Hospital setting, IC-informed consent, 
IG - Intervention group, IG1 - Intervention group1, IG2 - Intervention group 2, IL - Inadequate literacy, IN-intervention, INTV- interview, IV – Independent variable, LC – Lipid control, LDL- low-density lipoprotein, LOE- 
level of evidence, MA – Medication adherence,  MAQ-medication adherence questionnaire,  M –Mean, MC – Multiple comorbidities, MDHN – Medication dispensed by Home Nurse, meds- medications, MEMS- Medication 
event monitoring system, MI – Motivational interviewing  mos.- months, MDP – medication dispensed by pharmacy, MMAS-Morisky medication adherence scale, Mos-months, MPR- Medication Possession Ratio Measure, MR 
– Medication review, N – Sample (population), n – Sample size (studies), NS – Not stated, NCP- non-complaint patients, OR – Odds ratio, PCG - Placebo call group, PCDI - Patient centered discharge instructions PCP – Primary 
care physician, PCMO-primary care medical offices, PH – Pharmacist, PI- psychiatric illness, Pt – Patient, RCT – Randomized Controlled Trial, RA – renin-angiotensin agents, RD- renal disease, RF – renal failure, Rx – 
Prescription,  SAS - Statistical Analysis Software, SBP- systolic blood pressure, SC – Self-care, SD – Standard deviation, SE-self-efficacy, SPSS - Statistical Package for the Social Sciences, SS - # of study sites, STS- Structured 
telephone support, Sys – systolic, TAU – Treatment as usual, TI – Terminal illness, TM – Telemonitoring,  TC – Telephone call, UC- usual care, U.S.- United States, WFFQ- Willett Food Frequency Questionnaire, X2 – Chi 
square, Yrs – years, NO- Number of 
SMI: 95 
(SMI vs UC 
p=0.581) 
HEI: 98 (HEI 
vs. UC 
p=0.502) 
UC: 96 
 
Cohen’s 
D=1.08 
(large) 
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Cluster-
randomized 
trial of a 
physician/ 
pharmacist 
collaborative 
model to 
improve 
blood 
pressure 
control.  
 
Funding: 
National 
Heart, Lung, 
and Blood 
Collaborative 
model/team-
based care-ns 
To evaluate if 
a physician/ 
pharmacist 
collaborative 
model would 
be 
implemented 
as determined 
by improved 
bp control in 
pcmo with 
diverse 
geographic 
and patient 
characteristic 
and whether 
long-term bp 
control could 
be sustained. 
N=625 
n=224 UC group 
n=207 sustained 
care group 
n=194 brief 
intervention group 
(9 mos.) 
 
Subjects were 
recruited from 32 
medical offices in 
15 states.  
 
Demographics: 
over 50% were 
minorities, 49% 
mades less than 
$25,000 yearly, 
50% had DM or 
BP goal: less than 
140/90 for uncomp-
licated pts and 130/80 
for those with RD or 
DM.  
 
SC-RN, LPN, or M.A. 
recruited subjects and 
collected study data.  
BP 
measurements at 
baseline, 6, 9, 12, 
18, & 24 mos.  
Validated survey 
instrument for 
scoring clinical 
pharmacy 
services. JNC-7 
Guidelines. 
Omron HEM 
907-XL bp 
measurement 
device with 
standardized 
measurement 
techniques. 
Validated 4-item 
instrument used 
Randomizati
on, 
nonlinear 
mixed-
effects 
model, OR, 
intraclass 
correlation 
coefficient 
estimate, 
Lan-
Demets 
spending 
function, 
O’Brien-
Fleming 
stopping 
boundaries, 
conditional 
IV1: control 
group at 9 
mos. BP 
control =34% 
vs. 
DV1: IN 
group at 9 
mos. BP 
control =43% 
(adjusted OR, 
1.57 [95% 
CI, 0.99-
2.50]; 
P=0.059). 
 
DV2: BP 
control at 9 
mos. for 
minority 
LOE: 2 
 
Strengths: Cluster, randomized trial 
design, intent-to-treat analysis, 
controlled for covariances, 
standardized measurements, high 
utility to PICOT question and 
population, length of study,  
 
Weaknesses: no blinding, funding 
constraints lead to premature 
termination of some subjects, 
imbalances occurred in the study 
arms due to the cluster nature of the 
design, low power due to subjects 
dropping out of being lost to f/u, at 
baseline, the brief intervention group 
were more likely to be married and 
have private insurance. No way to 
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AA – Antihypertensive agent, AfAm- African Americans, AI- adherence intervention, ANCOVA- analysis of covariance, AT – Adherence therapy, BB- beta-blockers, BP – Blood pressure,  BAMQ – Beliefs about medications 
questionnaire, CA- Calcium antagonists, CBMC-community based medical center, CD- chronic disease, CKD- chronic kidney disease, CG – Control group, CHF- congestive heart failure, CI – Confidence interval, CogI – 
Cognitively impaired, CS – Community setting, CVD-cardiovascular disease, D – Diuretics, DBP – diastolic blood pressure, DM- diabetic, DRAW- drug adherence work-up tool, DV1 – Dependent variable 1, DV2 – Dependent 
variable 2, DV3 – Dependent variable 3, DV4 - Dependent variable 4, DV5- Dependent variable 5, Edu – Education, EF – Ejection fraction, EMR-electronic medical record, EP – Exercise program, ES – Educational session, f – 
female, FDN- Foundation, FE – Fisher’s exact test, F/U – Follow Up, FQHC- federally qualified health center, GTET- greater than or equal to, HF-heart failure, HTN-  Hypertension,  HS – Hospital setting, IC-informed consent, 
IG - Intervention group, IG1 - Intervention group1, IG2 - Intervention group 2, IL - Inadequate literacy, IN-intervention, INTV- interview, IV – Independent variable, LC – Lipid control, LDL- low-density lipoprotein, LOE- 
level of evidence, MA – Medication adherence,  MAQ-medication adherence questionnaire,  M –Mean, MC – Multiple comorbidities, MDHN – Medication dispensed by Home Nurse, meds- medications, MEMS- Medication 
event monitoring system, MI – Motivational interviewing  mos.- months, MDP – medication dispensed by pharmacy, MMAS-Morisky medication adherence scale, Mos-months, MPR- Medication Possession Ratio Measure, MR 
– Medication review, N – Sample (population), n – Sample size (studies), NS – Not stated, NCP- non-complaint patients, OR – Odds ratio, PCG - Placebo call group, PCDI - Patient centered discharge instructions PCP – Primary 
care physician, PCMO-primary care medical offices, PH – Pharmacist, PI- psychiatric illness, Pt – Patient, RCT – Randomized Controlled Trial, RA – renin-angiotensin agents, RD- renal disease, RF – renal failure, Rx – 
Prescription,  SAS - Statistical Analysis Software, SBP- systolic blood pressure, SC – Self-care, SD – Standard deviation, SE-self-efficacy, SPSS - Statistical Package for the Social Sciences, SS - # of study sites, STS- Structured 
telephone support, Sys – systolic, TAU – Treatment as usual, TI – Terminal illness, TM – Telemonitoring,  TC – Telephone call, UC- usual care, U.S.- United States, WFFQ- Willett Food Frequency Questionnaire, X2 – Chi 
square, Yrs – years, NO- Number of 
Institute 
 
Bias: no 
blinding 
 
Country: 
U.S. 
 
Prospective, 
multicenter 
trial.  
CKD. 
 
Inclusion: pcmo 
with an onsite 
clinical 
pharmacist, 
subjects had to 
provide IC.  
 
Exclusion: 
excessively high 
bp, CogI, recent 
heart attack, sleep 
apnea, angina, 
stroke, HF, RD, 
elevated liver 
tests, not a pt in 
the study office, 
declined mental 
status exam or 
withdrew consent 
 
Attrition: 133 
(21.3%) 
 
IV: control group 
that received UC 
 
DV1: 9-mo. PH 
IN (BI) 
 
DV2: 24-mo. PH 
IN (SI) 
to measure MA.  power, 
linear mixed 
model with 
random 
effects 
subjects 37% 
vs non-
minority 
subjects 28% 
(adjusted OR, 
1.54 [95% 
CI, 0.83-
2.86]; 
P=0.17). 
DV3: bp at 
24 mos.: 
IN group: 
63% vs. CG: 
46% 
(adjusted OR, 
1.84 [95% 
CI, 0.89-
3.78]; 
P=0.098). 
 
Cohen’s D= 
0.37= 
moderate 
control for medications changing, as 
control group was prescribed much 
more pharmacotherapy, which may 
have made the results insignificant, 
many adverse events reported, but 
not significant by arm/group.  
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AA – Antihypertensive agent, AfAm- African Americans, AI- adherence intervention, ANCOVA- analysis of covariance, AT – Adherence therapy, BB- beta-blockers, BP – Blood pressure,  BAMQ – Beliefs about medications 
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A practice-
based RCT 
to improve 
MA among 
Latinos with 
htn: study 
protocol for 
a RCT. 
Funding:  
 
Country:  
U.S. 
Common 
sense model of 
self-regulation 
(CSM) and 
Vrijens 
medications 
adherence 
taxonomy 
RCT with2 
arms 
N=148 
n=74 IG 
n=74 UC group 
sample was 
recruited from a 
cbmc. in New 
York. 
Inclusion: self- 
identify as Latino, 
gtet 18 years of 
age, has HTN & 
at least 1 CVD 
risk factor, takes 
an AA 
 
Exclusion: refuse 
or are unable to 
provide IC, 
already in another 
study, has PI 
 
Attrition: 10% at 
1 mo., 8% at 6 
mo. visit 
To evaluate the 
effectiveness of a 
culturally tailored, 
evidence-based AI 
delivered by bilingual 
health coaches vs. UC 
on MA at 6 mos. 
among 148 Latino pts 
with HTN who are 
uncontrolled and 
nonadherent to meds. 
Secondary aim was to 
evaluate the effect of 
AI vs. UC on bp 
reduction at 6 mos.  
UC care-standard htn 
treatment as 
determined by pcp 
AI group-received 6 
biweekly sessions 
with bilingual health 
coaches for 9 sessions 
HTN-bp>140/90 on at 
least 2 consecutive 
visits within the year 
or >130/80 for DM or 
RD pts. & at least 1 
CVD risk factor 
Morisky 
adherence scale, 
electronic 
monitoring 
device, validated 
automated BP 
device to assess 
BP, AI script, 
semi-structured 
interviews, 
EMR- embedded 
adherence 
intervention 
template, 
BAMQ, 
Comprehensive 
Assessment and 
referral 
evaluation 
dementia 
diagnostic scale, 
Illness 
perceptions 
questionnaire- 
revised, MA SE 
scale, Watchman 
automated 
device, 
Charleston 
comorbidity 
index, Test of 
=0.05 level 
for a 2-sided 
test, chi-
square test 
of 
independenc
e, ANOVA, 
logit model, 
logistic 
regression, 
2-sided tests 
of 
significance, 
OR, linear 
mixed 
effects 
regression 
models,  
MA at 6 
mos. visit: 
 
Within-pt 
change in 
sbp: 
 
Within-pt 
change in 
dbp: 
 
No data 
reported, 
trial began 
in October 
2012. N=112 
in 2015 and 
patient 
recruitment 
was still 
ongoing.  
LOE: 2 
 
Strengths: block randomization, 
utility to PICOT question, EMR for 
ease of use incorporates intervention 
into clinic workflow, all analyses 
were done in an intent-to-treat 
design 
 
Weaknesses: no blinding to group 
assignments, patients were 
financially compensated, which may 
not yield the same results in practice 
without compensation, high rate of 
patient refusal to participate, high 
rate of providers leaving the study 
site 
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functional health 
literacy in adults, 
treatment self-
regulation 
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primary care 
assessment 
survey 
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Citation: 
(Boutin-
Foster et al., 
2016). 
Title: 
Results from 
the trial 
using 
motivational 
interviewing
, positive 
affect, and 
self-
affirmation 
in AfAm’s 
with HTN 
(TRIUMPH) 
 
Funding: 
Center for 
Excellence 
in Health 
Social 
cognitive 
theory, 
positive affect 
theory 
The objective 
of the study 
was to 
improve BP 
control by 
targeting SE, 
a major 
determinant 
of MA. 
 
Two-arm 
RCT 
N=238 
n=122 CG 
n= 116 IG 
 
Adult pts who 
received care at 
FQHC’s and 
community 
ambulatory 
practices in South 
Bronx and 
Harlem, NYC. 
 
Demographics: 
M age: 56, 70% 
female, 70% had 
high school 
education 
 
Inclusion: self-
identified as 
AfAm, HTN 
SE-describes the 
confidence in one’s 
ability to take action 
to overcome barriers 
and is a major 
cornerstone of health 
behavior change. 
 
MI-based on the work 
done by Miller and 
Rollnick. Delivered 
during bimonthly 
telephone calls for 12 
mos. 
 
positive affect 
induction- based on 
positive affect theory, 
which states that 
positive affect enables 
individuals to be more 
open-minded, 
EMR, Charlson 
Comorbidity 
Index, 
psychosocial 
measures, htn hx, 
center for 
epidemiologic 
studies 
depression scale, 
MA SE scale, 
perceived stress 
scale, positive 
and negative 
affect scale, 
medical 
outcomes study-
social support 
survey, HTN 
workbook, 
behavior 
contract, BPTru 
Randomized 
in a 1:1 ratio 
to CG or IG, 
sample size 
calculations 
included a 
power of 
80% and 
standard test 
level of .05. 
chi-square 
and 
student’s t-
test, 
univariate 
logistic 
regression, 
multivariate 
model, 
SPSS 
 
Cohen’s D= 
BP control 
at 12 mos.: 
 
CG: 82.2% 
IG: 83.7% 
(OR=1.33, 
CI=.57-3.10, 
P=.50). 
 
LOE: II 
 
Strengths: intent-to-treat model, 
utility to PICOT, ease of feasibility, 
can be generalized to any 
intervention 
 
Weaknesses: Neither the 
participants nor the research 
assistants were blinded to the study 
intervention. High attrition rate. No 
cluster randomization, which may 
result in contamination. The same 
research assistants were used for the 
CG and IG. Both groups received 
telephone calls at the same time, 
effects were insignificant.  
MOTIVATIONAL INTERVIEWING IMPACT ON CVD          38 
AA – Antihypertensive agent, AfAm- African Americans, AI- adherence intervention, ANCOVA- analysis of covariance, AT – Adherence therapy, BB- beta-blockers, BP – Blood pressure,  BAMQ – Beliefs about medications 
questionnaire, CA- Calcium antagonists, CBMC-community based medical center, CD- chronic disease, CKD- chronic kidney disease, CG – Control group, CHF- congestive heart failure, CI – Confidence interval, CogI – 
Cognitively impaired, CS – Community setting, CVD-cardiovascular disease, D – Diuretics, DBP – diastolic blood pressure, DM- diabetic, DRAW- drug adherence work-up tool, DV1 – Dependent variable 1, DV2 – Dependent 
variable 2, DV3 – Dependent variable 3, DV4 - Dependent variable 4, DV5- Dependent variable 5, Edu – Education, EF – Ejection fraction, EMR-electronic medical record, EP – Exercise program, ES – Educational session, f – 
female, FDN- Foundation, FE – Fisher’s exact test, F/U – Follow Up, FQHC- federally qualified health center, GTET- greater than or equal to, HF-heart failure, HTN-  Hypertension,  HS – Hospital setting, IC-informed consent, 
IG - Intervention group, IG1 - Intervention group1, IG2 - Intervention group 2, IL - Inadequate literacy, IN-intervention, INTV- interview, IV – Independent variable, LC – Lipid control, LDL- low-density lipoprotein, LOE- 
level of evidence, MA – Medication adherence,  MAQ-medication adherence questionnaire,  M –Mean, MC – Multiple comorbidities, MDHN – Medication dispensed by Home Nurse, meds- medications, MEMS- Medication 
event monitoring system, MI – Motivational interviewing  mos.- months, MDP – medication dispensed by pharmacy, MMAS-Morisky medication adherence scale, Mos-months, MPR- Medication Possession Ratio Measure, MR 
– Medication review, N – Sample (population), n – Sample size (studies), NS – Not stated, NCP- non-complaint patients, OR – Odds ratio, PCG - Placebo call group, PCDI - Patient centered discharge instructions PCP – Primary 
care physician, PCMO-primary care medical offices, PH – Pharmacist, PI- psychiatric illness, Pt – Patient, RCT – Randomized Controlled Trial, RA – renin-angiotensin agents, RD- renal disease, RF – renal failure, Rx – 
Prescription,  SAS - Statistical Analysis Software, SBP- systolic blood pressure, SC – Self-care, SD – Standard deviation, SE-self-efficacy, SPSS - Statistical Package for the Social Sciences, SS - # of study sites, STS- Structured 
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square, Yrs – years, NO- Number of 
Disparities 
Research 
and 
Community 
Engagement 
 
Bias:  
contaminatio
n 
Country: 
U.S. 
diagnosis, on at 
least one AA, had 
elevated BP at 
time of 
recruitment, could 
provide consent.  
 
Exclusion: ns 
 
Attrition: 61 
(25.6%) 
motivated, and 
responsive to health 
messages, thus 
fostering their ability 
to achieve their 
personal goals. 
 
self-affirmation 
manipulation- 
describes the 
importance of 
focusing on personal 
strength and core 
values as a method of 
counteracting negative 
responses to stress and 
maintaining 
psychological well-
being. 
 
HTN- bp>140/90 on 
average or >130/80 
for DM or RD pts. & 
at least 1 CVD risk 
factor 
 
IV: BP 
DV: MI and support 
0.11=small 
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(Barker-
Collo et al., 
2015).  
 
Title: 
Improving A
dherence to 
Secondary 
Stroke 
Prevention 
Strategies 
Through MI: 
RCT. 
Bias: 
None 
 
Funding: 
New 
Zealand 
Health 
Research 
Council 
 
Country: 
New 
Zealand 
Cognitive 
behavioral 
psychotherapy
- ns 
Single-blind, 
prospective 
phase 
III RCT 
 
Purpose: 
tested 
effectiveness 
of MI for 
reducing 
stroke 
recurrence, 
measured by 
improving ad
herence to 
recommended
 meds and 
lifestyle 
changes 
compared 
with usual 
care. 
 
 
N=386 
n= 193 IG 
n= 193 CG 
 
Inclusion: stroke 
within 28 days, 
able to provide 
consent, gtet age 
16 
 
Exclusion: 
subarachnoid 
hemorrhage, 
recurrent stroke, 
not in region, 
CogI, 
communication 
difficulties, too 
unwell, discharge 
to rest home/care, 
passed 
randomisation 
timeframe, PI, in 
another study, not 
available for f/u, 
not contactable, 
other 
 
Attrition: 
39 (10.10%) 
MI treatment- 4 
sessions at 28 days, 3, 
6, & 9 mos. post 
stroke via telephone 
or face-to face 
interviews 
 
IV: change in SBP 
and LDL cholesterol 
at 12 mos.  
 
DV: self-reported 
adherence, new 
stroke, or coronary 
heart disease events, 
quality of life, and 
mood 
 
MA-determined by 
asking the pt if they 
had taken all of their 
meds as prescribed in 
the last 7 days and if 
not then specifying 
the details 
Hospital Anxiety 
and Depression 
Scale, Short 
Form-36, online 
randomisation 
service, 
minimization 
randomization, 
Barthel Index 
 
SAS, all 
tests were 2-
sided with a 
5% level of 
significance, 
unadjusted 
relative 
risks, 
generalized 
linear 
regression 
models, 
random 
effects 
mixed 
models, 
model 
adjusted 
mean 
differences, 
odds ratios, 
95% CI, 
sensitivity 
analysis 
 
Cohen’s 
D=0.36= 
moderate 
BP M 
difference in 
change, -
0.2.35 [95% 
confidence 
interval, -
6.16 to 1.47] 
cholesterol 
(mean 
difference in 
change, -
0.0.12 [95% 
confidence 
interval, -
0.30 to 0.06]) 
effects on 
self-
reported  
MA at 6 
months 
(1.979; 95% 
confidence 
interval, 
0.98-3.98; 
P=0.0557) 
 and 9 
months 
(4.295; 95% 
confidence 
interval, 
1.56-11.84; 
P=0.0049) 
post stroke. 
 
LOE: II 
 
Strengths: treatment allocation was 
concealed from staff, researchers 
who provided the intervention were 
not involved in data analysis, intent-
to-treat principle 
 
Weaknesses: utility to PICOT 
question, generalizability, use of 
last-value-carried forward for 
missing data, couldn’t blind 
participants 
MOTIVATIONAL INTERVIEWING IMPACT ON CVD          40 
AA – Antihypertensive agent, AfAm- African Americans, AI- adherence intervention, ANCOVA- analysis of covariance, AT – Adherence therapy, BB- beta-blockers, BP – Blood pressure,  BAMQ – Beliefs about medications 
questionnaire, CA- Calcium antagonists, CBMC-community based medical center, CD- chronic disease, CKD- chronic kidney disease, CG – Control group, CHF- congestive heart failure, CI – Confidence interval, CogI – 
Cognitively impaired, CS – Community setting, CVD-cardiovascular disease, D – Diuretics, DBP – diastolic blood pressure, DM- diabetic, DRAW- drug adherence work-up tool, DV1 – Dependent variable 1, DV2 – Dependent 
variable 2, DV3 – Dependent variable 3, DV4 - Dependent variable 4, DV5- Dependent variable 5, Edu – Education, EF – Ejection fraction, EMR-electronic medical record, EP – Exercise program, ES – Educational session, f – 
female, FDN- Foundation, FE – Fisher’s exact test, F/U – Follow Up, FQHC- federally qualified health center, GTET- greater than or equal to, HF-heart failure, HTN-  Hypertension,  HS – Hospital setting, IC-informed consent, 
IG - Intervention group, IG1 - Intervention group1, IG2 - Intervention group 2, IL - Inadequate literacy, IN-intervention, INTV- interview, IV – Independent variable, LC – Lipid control, LDL- low-density lipoprotein, LOE- 
level of evidence, MA – Medication adherence,  MAQ-medication adherence questionnaire,  M –Mean, MC – Multiple comorbidities, MDHN – Medication dispensed by Home Nurse, meds- medications, MEMS- Medication 
event monitoring system, MI – Motivational interviewing  mos.- months, MDP – medication dispensed by pharmacy, MMAS-Morisky medication adherence scale, Mos-months, MPR- Medication Possession Ratio Measure, MR 
– Medication review, N – Sample (population), n – Sample size (studies), NS – Not stated, NCP- non-complaint patients, OR – Odds ratio, PCG - Placebo call group, PCDI - Patient centered discharge instructions PCP – Primary 
care physician, PCMO-primary care medical offices, PH – Pharmacist, PI- psychiatric illness, Pt – Patient, RCT – Randomized Controlled Trial, RA – renin-angiotensin agents, RD- renal disease, RF – renal failure, Rx – 
Prescription,  SAS - Statistical Analysis Software, SBP- systolic blood pressure, SC – Self-care, SD – Standard deviation, SE-self-efficacy, SPSS - Statistical Package for the Social Sciences, SS - # of study sites, STS- Structured 
telephone support, Sys – systolic, TAU – Treatment as usual, TI – Terminal illness, TM – Telemonitoring,  TC – Telephone call, UC- usual care, U.S.- United States, WFFQ- Willett Food Frequency Questionnaire, X2 – Chi 
square, Yrs – years, NO- Number of 
 
Citation 
 
  
Theory/ 
Conceptual 
Framework 
Design/ 
Method/ 
Purpose 
Sample/Setting Major Variables 
Studied and 
Their Definitions 
Measurement/ 
Instrumentation 
Data 
Analysis 
Findings/ 
Results 
Level of evidence/ 
Decision for Use/Application to 
Practice 
(Stewart et 
al., 2014). 
 
Title: A 
multifaceted 
pharmacist 
intervention 
to improve 
antihyperten
sive 
adherence: a 
cluster-
randomized, 
controlled 
trial (HAPPy 
trial) 
 
Bias: recall 
bias 
 
Funding: ns 
 
Country: 
Australia 
 
Ns- self-care 
model 
To evaluate a 
community 
PH IV to 
improve 
adherence 
with AA with 
a view to 
improving BP 
control.  
A 
prospective, 
non-blinded, 
cluster-
randomized, 
controlled 
trial 
N=395 
n=207 IG 
n= 188 CG 
 
Demographics: 
M age: 66.7 yrs., 
51.1% males 
 
Inclusion: Adults 
with primary HTN 
who obtained 
AA’s within the 
previous 6 mos. 
those with poor 
refill adherence 
were 
preferentially 
identified, gtet 18 
years of age, 
available for f/u at 
6 mos. from 
baseline 
 
Exclusion: 
participation in 
other adherence 
Primary outcome: 
change in proportion 
self-reporting MA. 
 
Secondary outcome: 
BP change 
 
BP- if bp differed by 
more than 10mmHG 
for SBP or 5 mmHg 
for DBP, a third 
reading was taken and 
the average of the 2 
closest readings was 
recorded.  
PhARIA, 
MedeMineCVD, 
FRED Dispense, 
intracluster 
correlation 
coefficients, 
cluster 
randomization. 
OMRON HEM-
790IT, Morisky 
scale, Tool for 
Adherence 
Behaviour 
Screening 
SAS version 
9.2, chi-
square tests 
for equal 
proportion 
reported as 
numbers 
(percentages
). 
Continuous 
normally 
distributed 
variables 
were 
compared 
using 
Student 
t 
-tests and 
reported as 
means 
(standard 
deviations) 
whereas 
non-
normally 
distributed 
proportion 
of adherent 
participants 
increased in 
both groups 
but was not 
significantly 
different 
between 
groups 
[57.2% to 
63.6% 
(control) vs. 
60.0% to 
73.5% 
(intervention)
, P = 0.23]. 
The mean 
reduction in 
systolic BP 
was 
significantly 
greater in the 
intervention 
group 
(10.0 mmHg 
vs. 
LOE: II 
 
Strengths: intent-to-treat principle, 
ease of pt recruitment, 
multidisciplinary approach, sample 
size and low rate of attrition 
  
Weaknesses: ease of use, 
Hawthorne effect, recall bias, poor 
participant recall, possible low 
sensitivity to change, possible 
intensified prescribing, possibility of 
PH’s falsifying BP results, uncertain 
of adherence due to short time span 
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level of evidence, MA – Medication adherence,  MAQ-medication adherence questionnaire,  M –Mean, MC – Multiple comorbidities, MDHN – Medication dispensed by Home Nurse, meds- medications, MEMS- Medication 
event monitoring system, MI – Motivational interviewing  mos.- months, MDP – medication dispensed by pharmacy, MMAS-Morisky medication adherence scale, Mos-months, MPR- Medication Possession Ratio Measure, MR 
– Medication review, N – Sample (population), n – Sample size (studies), NS – Not stated, NCP- non-complaint patients, OR – Odds ratio, PCG - Placebo call group, PCDI - Patient centered discharge instructions PCP – Primary 
care physician, PCMO-primary care medical offices, PH – Pharmacist, PI- psychiatric illness, Pt – Patient, RCT – Randomized Controlled Trial, RA – renin-angiotensin agents, RD- renal disease, RF – renal failure, Rx – 
Prescription,  SAS - Statistical Analysis Software, SBP- systolic blood pressure, SC – Self-care, SD – Standard deviation, SE-self-efficacy, SPSS - Statistical Package for the Social Sciences, SS - # of study sites, STS- Structured 
telephone support, Sys – systolic, TAU – Treatment as usual, TI – Terminal illness, TM – Telemonitoring,  TC – Telephone call, UC- usual care, U.S.- United States, WFFQ- Willett Food Frequency Questionnaire, X2 – Chi 
square, Yrs – years, NO- Number of 
promotion 
programs, had a 
PH-conducted 
med review in the 
last 12 mos., non-
English speaking, 
not self-
administering 
AA’s.  
 
Attrition: 41 
(10.4%) 
variables 
were 
compared 
using 
Wilcoxon 
rank sum 
tests and 
reported as 
medians 
(interquartile 
range). To 
control for 
the effects of 
cluster 
randomizati
on, group 
changes 
were 
compared 
using mixed 
linear and 
nonlinear 
modelling 
for normally 
and non-
normally 
distributed 
data, with 
individual 
pharmacies 
treated as a 
random 
effect. 18 
Differences 
from cluster-
4.6 mmHg; 
P = 0.05). 
The 
proportion 
of patients 
who were 
non-
adherent at 
baseline and 
adherent at 
6 months 
was 22.6% 
(95%CI 5.1-
40.0%) 
higher in the 
intervention 
group (61.8% 
vs. 39.2%, 
P = 0.007). 
Among 
participants 
with baseline 
BP above 
target, 
reduction of 
systolic BP 
was 
significantly 
greater in the 
intervention 
group [by 
7.2 mmHg 
(95%CI 1.6-
12.8 mmHg); 
(P = 0.01)]. 
MOTIVATIONAL INTERVIEWING IMPACT ON CVD          42 
AA – Antihypertensive agent, AfAm- African Americans, AI- adherence intervention, ANCOVA- analysis of covariance, AT – Adherence therapy, BB- beta-blockers, BP – Blood pressure,  BAMQ – Beliefs about medications 
questionnaire, CA- Calcium antagonists, CBMC-community based medical center, CD- chronic disease, CKD- chronic kidney disease, CG – Control group, CHF- congestive heart failure, CI – Confidence interval, CogI – 
Cognitively impaired, CS – Community setting, CVD-cardiovascular disease, D – Diuretics, DBP – diastolic blood pressure, DM- diabetic, DRAW- drug adherence work-up tool, DV1 – Dependent variable 1, DV2 – Dependent 
variable 2, DV3 – Dependent variable 3, DV4 - Dependent variable 4, DV5- Dependent variable 5, Edu – Education, EF – Ejection fraction, EMR-electronic medical record, EP – Exercise program, ES – Educational session, f – 
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Prescription,  SAS - Statistical Analysis Software, SBP- systolic blood pressure, SC – Self-care, SD – Standard deviation, SE-self-efficacy, SPSS - Statistical Package for the Social Sciences, SS - # of study sites, STS- Structured 
telephone support, Sys – systolic, TAU – Treatment as usual, TI – Terminal illness, TM – Telemonitoring,  TC – Telephone call, UC- usual care, U.S.- United States, WFFQ- Willett Food Frequency Questionnaire, X2 – Chi 
square, Yrs – years, NO- Number of 
adjusted 
models have 
been 
reported 
with 95% 
CI. A 
two-sided 
P-value 
≤ 0.05 was 
statistically 
significant 
 
Among 
participants 
non-adherent 
at baseline 
and above 
target BP, the 
proportion 
reporting ad
herence at 
6 months 
was 
significantly 
greater in the 
intervention 
group [56.8% 
vs. 35.9%, 
P = 0.039). 
Cohen’s D: 
0.89= large 
Citation 
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Level of evidence/ 
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routines and 
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among 
hypertensive 
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Americans. 
 
Country:  
NS (Self-Care 
Theory) 
Design:  
Practice-
based RCT 
 
Purpose: To 
1) identify 
pt 
sociodemogra
phic factors 
that are 
associated 
N – 190 
IG – 64 
CG – 64 
Demographics: 
f- 88%, m – 12% 
M age – 54 yrs 
Medicaid-74% 
High school Edu- 
23% 
Unemployed- 
54% 
BP (<140/90) 
MI-4 sessions of 
behavioral counseling 
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mos. Intervals 
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days in which pts took 
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IV1 – MA with med-
taking consistency 
DV1 – DBP with 
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test,1-way 
analysis of 
variance, X2 
& 
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At 9 mos. 
IV1- 
(F=9.54, 
p=.002) 
DV1- (OR, 
1.319; 95% 
CI, 0.410–
4.246; P= 
.642)  
 
DV2- (OR, 
Level of Evidence: LOE II 
 
Strengths: Strong methodology, 
power analysis done & reliable 
instruments 
 
Weaknesses: May not be 
generalizable, electronic monitoring 
was used, and cannot confirm that 
doses were actually taken 
Conclusions: Aiding pts with HTN 
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Bias: None 
 
with having a 
consistent 
med-taking 
routine; (2) 
examine the 
association 
between med-
taking 
consistency 
and MA over 
a 9-month 
monitoring 
period; and 
(3) examine 
the 
association 
between med-
taking 
consistency 
and BP 
control. 
 
Single-44% 
Setting: 30 referral 
metropolitan 
hospital in 
Australia. 
Inclusion: 
hypertensive 
African 
Americans 
receiving care 
from two primary- 
care facilities 
affiliated with 
New York 
Presbyterian 
Hospital’s 
Ambulatory Care 
Network (ACN). 
 
Exclusion: 
None, 190 were 
eligible and data 
exists for 190 pts 
 
Attrition: n/a 
 
consistency index 
DV2 – SBP with 
consistency index 
 
 
 
0.621; 95% 
CI, 0.195-
1.974; 
p=.419) 
 
Cohen’s D= 
0.14 (small) 
in establishing a consistent med-
taking routine is more likely to 
increase adherence to meds and 
improve BP control.  
 
Feasibility: Recommended for use 
in practice due to increase in 
adherence of TCP by interventions 
including continued nursing support 
via telephone. 
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Appendix B 
Table 2 
Synthesis Table 
 
Author (Solomon 
et al.). 
Stewart 
et al.). 
(Barker-
Collo et 
al.).  
 
(Boutin-
Foster et 
al.). 
(Carter 
et al.).  
 
(Schoentha-
ler et al.). 
 
(Ogedeg-
be et al.). 
 
(Alhalai-
qa et al.).  
 
(Friedbe-
rg et al.). 
 
(Hedegaa-
rd et al.). 
Year  2012 2014 2015 2016 2015 2015 
 
2008 2012 2015 
 
2015 
LOE II II II II II II II II II II 
Country U.S. Austra-
lia 
New 
Zealand 
U.S. U.S. U.S. U.S. U.K. U.S. Denmark 
Study Characteristics 
Bias none recall none C. B. No bl. none C.B. selection none C.B. 
Age (mean 
yrs.) 
54 66.7  ns 56 61.8 ns 54 53 66.4 62 
Ethnicity Af. 
Am. 
mixed mixed Af. Am. mixed Latino Af. Am.  ns mixed ns 
Gender f- 88% m-
51.1% 
ns f-77% f-61.3% ns f-88% f-54% m-98.9% m-60% 
Setting  pharm        Hospital  
Office/pr. care X  x x x x x x x  
N 190 395 386 238 625 148 190 136 533 532 
Measurement 
tools 
MEMS, 
Power-
view 
PhARI
A, 
Mede-
Mine-
CVD, 
HADS, 
Short 
Form-
36, 
online 
EMR, CCI, 
psycho-
social 
measures, 
htn hx, 
BP 
measure
ments,  
survey 
MS, EMD, 
BP device 
script, 
interviews, 
EMR, MA SE 
Charlson 
Comorbidi
ty Index, 
MEMS, 
clinic bp 
SBP, 
BAMQ, 
MMAS, 
mercury 
syphymo
Omron 
HEM 
907XL 
DRAW, 
MAQ, SBP, 
DBP 
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FRED 
Dispens
e, 
OMRO
N 
HEM-
790IT, 
MS, 
TABS 
random-
isation 
service, 
Barthel 
Index 
 
CESDS, 
MA SE 
scale, 
behavior 
contract, 
BPTru 
instrume
nt for 
scoring 
clinical 
pharmac
y 
services, 
4-item 
instrume
nt used 
to 
measure 
MA. 
scale, 
multiple 
surveys 
readings, 
mercury 
sphygmom
anometers 
mano-
meter 
Duration of 
IN 
9 mos.  6 mos. 12 mos.  9 mos. 6 mos. 12 mos. 11 weeks 6 mos. 12 mos. 
Gen. pop  x x  x      
Intervention  
MI x  x x   x   x 
CBT       x  x  
Telephone 
calls 
  x x x    x x 
In-office 
visits 
x  x  x   x   
Change/add 
rx 
x      x    
Med. adh x     x  x x x 
MEMS x      x x  x 
Outcomes 
Beh. change   x    x  x  
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SBP x x   x  x x x x 
DBP     x  x x   
Perc. Incr. 
QOL 
   x       
Impr. MA x x x     x x x 
Reduce stroke   x        
Reduce lipids   x       x 
MOTIVATIONAL INTERVIEWING IMPACT ON CVD          47 
 
Appendix C 
Figure 1 
Bandura’s Social Cognitive Theory 
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Appendix D 
Budget Plan 
 
Direct Costs: 
1. Survey monkey $384/year ($32/mo.) (planning to survey participants online for anonymity)  
Indirect Costs: 
1. Project leader’s time ($33 (RN base pay) x 420 hours (number from DNP 712 credit requirements)) =$13,860.00  
Total Cost: 
1. $14,244.00 (though site will be saving time, money, and energy by addressing staff health without having to pay for RN 
contributions) 
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Appendix E 
Figure 2 
JBI Model 
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Appendix F 
 
Table 2 
Summary Statistics Table for Interval and Ratio Variables 
Variable M SD n SEM Min Max Skewness Kurtosis 
PRE excessive worry or anxiety 24.90 133.18 30 24.31 0.00 730.00 5.20 25.03 
PRE feeling_upset_downhearted_or_blue 0.47 1.01 30 0.18 0.00 3.00 1.84 1.69 
PRE frustration irritation or close to losing your temper 0.63 1.27 30 0.23 0.00 6.00 2.86 8.85 
PRE general_fatigue_tiredness_or_weakness 0.37 0.49 30 0.09 0.00 1.00 0.55 -1.69 
PRE I am confident that I could deal efficiently with unexpected events 3.33 0.61 30 0.11 2.00 4.00 -0.28 -0.66 
PRE I can solve most problems if I invest the necessary effort 3.30 0.60 30 0.11 2.00 4.00 -0.18 -0.60 
PRE No matter what comes my way I’m usually able to handle it 3.33 0.48 30 0.09 3.00 4.00 0.71 -1.50 
PRE trouble falling asleep or staying asleep  1.28 1.36 29 0.25 0.00 3.00 0.27 -1.73 
PRE under or overweight 0.70 0.47 30 0.09 0.00 1.00 -0.87 -1.24 
PRE When I am confronted with a problem I can usually find several solutions 3.30 0.65 30 0.12 2.00 4.00 -0.37 -0.71 
Note. '-' denotes the sample size is too small to calculate statistic. 
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Appendix G 
Table 3 
Summary Statistics Table for Interval and Ratio Variables 
 
Note. '-' denotes the sample size is too small to calculate statistic. 
 
                         
Variable M SD n SEM Min Max Skewness Kurtosis 
POST feeling upset downhearted or blue 0.46 0.96 28 0.18 0.00 3.00 1.76 1.51 
POST frustration irritation or close to losing your temper 0.32 0.72 28 0.14 0.00 3.00 2.44 5.51 
POST general fatigue tiredness or weakness 0.29 0.46 28 0.09 0.00 1.00 0.95 -1.10 
POST I am confident that I could deal efficiently with unexpected events 3.25 0.52 28 0.10 2.00 4.00 0.30 -0.31 
POST I can solve most problems if I invest the necessary effort 3.39 0.50 28 0.09 3.00 4.00 0.44 -1.81 
POST No matter what comes my way I’m usually able to handle it 3.29 0.53 28 0.10 2.00 4.00 0.18 -0.56 
POST trouble falling asleep or staying asleep 27.18 137.75 28 26.03 0.00 730.00 5.00 23.03 
POST under or overweight 0.68 0.48 28 0.09 0.00 1.00 -0.76 -1.42 
POST When I am confronted with a problem I can usually find several solutions 3.36 0.56 28 0.11 2.00 4.00 -0.07 -0.82 
POST excessive worry or anxiety 26.46 137.88 28 26.06 0.00 730.00 5.00 23.04 
